Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
gptkb:state-owned_enterprise |
| gptkbp:abbreviation |
gptkb:China_National_Pharmaceutical_Group_Corporation
|
| gptkbp:country |
gptkb:China
|
| gptkbp:founded |
1998
|
| gptkbp:headquarters_location |
gptkb:Beijing
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sinopharm
|
| gptkbp:industry |
healthcare
pharmaceuticals |
| gptkbp:listedOn |
gptkb:Fortune_Global_500
|
| gptkbp:notableProduct |
gptkb:Sinopharm_BIBP_COVID-19_vaccine
gptkb:Sinopharm_WIBP_COVID-19_vaccine |
| gptkbp:numberOfEmployees |
over 100,000
|
| gptkbp:parentOrganization |
gptkb:State-owned_Assets_Supervision_and_Administration_Commission_of_the_State_Council
|
| gptkbp:product |
pharmaceuticals
medical equipment vaccines |
| gptkbp:revenue |
over 70 billion USD (2022)
|
| gptkbp:stockExchange |
gptkb:Hong_Kong_Stock_Exchange
|
| gptkbp:subsidiary |
gptkb:China_National_Pharmaceutical_Group
|
| gptkbp:website |
http://www.sinopharm.com/
|
| gptkbp:bfsParent |
gptkb:COVID-19
|
| gptkbp:bfsLayer |
4
|